These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34981317)

  • 1. Identification of the specific causes of polysorbate 20 degradation in monoclonal antibody formulations containing multiple lipases.
    Zhang S; Riccardi C; Kamen D; Reilly J; Mattila J; Bak H; Xiao H; Li N
    Pharm Res; 2022 Jan; 39(1):75-87. PubMed ID: 34981317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degradation of Polysorbate 20 by Sialate O-Acetylesterase in Monoclonal Antibody Formulations.
    Zhang S; Xiao H; Li N
    J Pharm Sci; 2021 Dec; 110(12):3866-3873. PubMed ID: 34487744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic degradation pattern of polysorbate 20 impacts interfacial properties of monoclonal antibody formulations.
    Gregoritza K; Theodorou C; Heitz M; Graf T; Germershaus O; Gregoritza M
    Eur J Pharm Biopharm; 2024 Jan; 194():74-84. PubMed ID: 38042510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative Phospholipase B-Like 2 is Not Responsible for Polysorbate Degradation in Monoclonal Antibody Drug Products.
    Zhang S; Xiao H; Goren M; Burakov D; Chen G; Li N; Tustian A; Adams B; Mattila J; Bak H
    J Pharm Sci; 2020 Sep; 109(9):2710-2718. PubMed ID: 32534029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
    Doshi N; Martin J; Tomlinson A
    Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring polysorbate hydrolysis in therapeutic proteins using an ultrasensitive extraction-free fatty acid quantitation method.
    Zhang S; Riccardi C; Kamen D; Xiao H; Li N
    Anal Biochem; 2022 Jan; 637():114472. PubMed ID: 34801481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
    Tomlinson A; Zarraga IE; Demeule B
    Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-in-one stability indicating polysorbate 20 degradation root-cause analytics via UPLC-QDa.
    Carle S; Evers DH; Hagelskamp E; Garidel P; Buske J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jan; 1232():123955. PubMed ID: 38128165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins.
    Aryal B; Lehtimaki M; Rao VA
    Pharm Res; 2024 Jun; 41(6):1217-1232. PubMed ID: 38740663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the polysorbate degradation fingerprints and kinetics of lipases - how the activity of polysorbate degrading hydrolases is influenced by the assay and assay conditions.
    Glücklich N; Carle S; Buske J; Mäder K; Garidel P
    Eur J Pharm Sci; 2021 Nov; 166():105980. PubMed ID: 34419573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations.
    Doshi N; Demeule B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3792-804. PubMed ID: 26419285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80.
    Glücklich N; Dwivedi M; Carle S; Buske J; Mäder K; Garidel P
    Int J Pharm; 2020 Dec; 591():119934. PubMed ID: 33059015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How enzymatic hydrolysis of polysorbate 20 influences colloidal protein stability.
    Glücklich N; Carle S; Diederichs T; Buske J; Mäder K; Garidel P
    Eur J Pharm Sci; 2023 Dec; 191():106597. PubMed ID: 37770006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.
    Doshi N; Giddings J; Luis L; Wu A; Ritchie K; Liu W; Chan W; Taing R; Chu J; Sreedhara A; Kannan A; Kei P; Shieh I; Graf T; Hu M
    Pharm Res; 2021 Mar; 38(3):531-548. PubMed ID: 33713012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.
    Zhang J; He J; Smith KJ
    J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polysorbate Degradation and Particle Formation in a High Concentration mAb: Formulation Strategies to Minimize Effect of Enzymatic Polysorbate Degradation.
    Roy I; Patel A; Kumar V; Nanda T; Assenberg R; Wuchner K; Amin K
    J Pharm Sci; 2021 Sep; 110(9):3313-3323. PubMed ID: 34077768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of long-term polysorbate degradation according to short-term degradation kinetics.
    Zhang S; Riccardi C; Carlson D; Kamen D; Graham KS; Shameem M; Bak H; Xiao H; Li N
    MAbs; 2023; 15(1):2232486. PubMed ID: 37415319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics.
    Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC
    J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics.
    Kishore RS; Kiese S; Fischer S; Pappenberger A; Grauschopf U; Mahler HC
    Pharm Res; 2011 May; 28(5):1194-210. PubMed ID: 21369824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.